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Soft tissue sarcomas (STS) represent a rare entity of malignant
disorders of various histologies with mostly aggressive characteris-
tics both locally and in the formation of distant metastases. In
contrast to a variety of other malignancies and with exceptions
reported in only a few trials and/or analyses (Gherlinzoni et al,
1986; Ravaud et al, 1990; Antman, 1997; Sarcoma Meta-Analysis
Collaboration, 1997), adjuvant chemotherapy has not shown to
significantly improve relapse-free and/or overall survival in
patients with STS. Similarly, chemotherapeutic interventions in
metastatic STS were generally also disappointing (Borden et al,
1990; Antman et al, 1993). Thus, cure of early disease obviously
depends upon appropriate, well-designed interdisciplinary therapy
of the primary tumour, including surgery, radiotherapy and – in
some cases (Rosenberg et al, 1982; Brodowicz et al, 1997; Sarcoma
Meta-Analysis Collaboration, 1997) – cytotoxic chemotherapy.
Based upon the above considerations of an obviously limited
efficacy of chemotherapeutic drugs upon the control of prolifera-
tion and/or induction of apoptosis in STS, alternate approaches
were sought. Although the underlying reasons have not been clari-
fied, certain STS cell lines have been demonstrated to be inhibited
in their proliferation by retinoids (Gabbert et al, 1988; Crouch and
Helman, 1991) and/or interferon-a (IFN-a; Rosso et al, 1992) in
vitro and in vivo. In order to follow and further expand these early
experiments, and put them into perspective with recent insights
into the regulation of proliferation inhibition and generation of
apoptosis on the molecular level, we have investigated the induc-
tion of these phenomena by a series of retinoids (9-cis-retinoic
acid (9cRA), 13-cis-retinoic acid (13cRA), all-trans retinoic acid
(tRA)) and IFN-a in various human STS cell lines including
HTB-82 (rhabdomyosarcoma), HTB-91 (fibrosarcoma), HTB-92
(liposarcoma), HTB-93 (synovial sarcoma) and HTB-94 (chon-
drosarcoma) in vitro and put them into context with p53 genotype
as well as p53 protein expression. This was of particular interest,
as growth arrest and induction of apoptosis resulting from
appropiate chemo- and/or radiotherapeutic measures have been
demonstrated to be dependent upon the intact function of the p53
gene in various models (Bergh et al, 1995; Elledge et al, 1995;
Sarkis et al, 1995). Thus, patients with testicular tumours with
regular p53 function have been shown to respond particularly well
to chemotherapy (Lutzker and Levine, 1996), whereas patients
with malignancies exhibiting high frequency of p53 mutations are
known to present often with resistance to chemotherapeutic agents
(Aas et al, 1996). In the present paper, we report that IFN-a
induced inhibition of proliferation of all cell lines irrespective of
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their p53 status, whereas retinoid-induced apoptosis was dose- and
time-related, depended upon the presence of regular p53 and
differed between retinoid preparations and, finally, STS cell lines.
MATERIALS AND METHODS
Cell cultures
Cell lines were obtained from American Type Culture Collection
(ATCC). HTB-82 (A-204, human rhabdomyosarcoma) were
cultured in McCoy’s 5A medium supplemented with 10% heat-
inactivated fetal calf serum (FCS; all from Gibco, Life
Technologies Ltd, Paisley, UK), 50 U ml–1 penicillin, 50 mg ml–1
streptomycin and 2 mML -glutamine (all from HyClone, Europe
Ltd, Cramlington, UK). The human STS cell lines HTB-91
(fibrosarcoma, SW 684), HTB-92 (liposarcoma, SW 872), HTB-
93 (synovial sarcoma, SW 982) and HTB-94 (chondrosarcoma,
SW 1353) were cultured in Leibovitz’s L-15 medium with L-gluta-
mine (PAA Laboratories Gmbh, Linz, Austria) supplemented with
10% heat-inactivated FCS (Gibco), 50 U penicillin and 50 mg
streptomycin (all from HyClone) per ml. HTB-91, HTB-92, HTB-
93 and HTB-94 were grown as monolayers (standard conditions)
in T75 flasks (Falcon, Becton Dickinson, NJ, USA) at 37°C in a
humidified atmosphere with free gas exchange without carbon
dioxide (CO2) by seeding 5 ´ 106 cells in 25 ml of appropriate
medium. HTB-82 cells were cultured in a humidified atmosphere
containing 5%.
Chemicals
9cRA, 13cRA and tRA (Biomol Research Laboratories, Inc.,
Plymouth Meeting, PA, USA) were dissolved in 1 ml dimethyl
sulphoxide (Sigma, St Louis, MO, USA) at a concentration
of 8.3 ´ 10–5 M and then diluted with the appropriate culture
medium (final concentrations: 10–7 M, 10–6 M and 10–5 M).
Retinoid stock solution was kept at – 20°C. Experiments with
retinoids were performed in subdued yellow light. Then, 5 ´ 106
IU IFN-a-2b (Schering-Plough NJ, USA) was dissolved in 1 ml
of distilled water and subsequently diluted in appropriate culture
medium (final concentrations: 25 U ml–1, 50 U ml–1, 100 U ml–1
and 1000 U ml–1).
DNA probes
Hybridization probes were isolated from plasmids containing: 0.6-
kb PstI cDNA fragment from human retinoic acid recepter (RAR)-
a (clone p63) in pTZ19R (ATCC); 0.6-kb EcoRI cDNA fragment
from human RAR-b in pSG5 (kind gift from Dr P Chambon,
INSERM, Illkirch, France); 1.3-kb EcoRI/AvaI cDNA fragment
from human RAR-g in pSG5 (kind gift from Dr P Chambon); 1.3-
kb  EcoRI/HindIII cDNA fragment from rat glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in pSP65. Isolation of inserts
were performed as described previously (Harant et al, 1995).
Cell proliferation assay [(3H) Thymidine incorporation
assay]
Tumour cells were plated in 96-well microtitre plates (Costar,
Cambridge, MA, USA) at a density of 5 ´ 104 cells per well.
Subsequently, retinoid and/or IFN-a-2b preparations in varying
concentrations were added to tumour cell lines (see above), which
had adhered for 1 h, and subsequently cultured for 48, 72, 96 and
120 h at 37°C under the appropriate conditions (HTB-82 cells
were cultured in a humidified atmosphere containing 5% CO2,
whereas all other cell lines were cultured in a humidified
Table 1 p53 gene mutations characterized in five human soft tissue
sarcoma cell lines
Cell line Base change Exon/codon Amino acid change
HTB-91 ATC to AAC 7/251 Ile–Asn
(fibrosarcoma)
HTB-92 GTG to TTG 6/203 Val–Leu
(liposarcoma)
HTB-94 CGA to TGA 6/213 Arg–STOP
(chondrosarcoma)
HTB-94 TTC to TTT 10/341 Phe–Phe; silent
(chondrosarcoma)
HTB-82 CGA to CGG 6/213 Arg–Arg; silent
(rhabdomyosarcoma)
HTB-93 Wild-type
(synovial sarcoma)
Table 2 Correlation of p53-status with proliferation inhibition and apoptosis
p53 Mutationa Proliferation inhibition Apoptosis induction
Cell line Interferon-a Retinoids 9cRA tRA 13cRA
HTB-82 No Yes Yes No Yes No
(rhabdomyosarcoma)
HTB-91 Yes Yes No No No No
(fibrosarcoma)
HTB-92 Yes Yes No No No No
(liposarcoma)
HTB-93 No Yes Yes Yes Yes No
(synovial sarcoma)
HTB-94 Yes Yes No No No No
(chondrosarcoma)
aAs assessed by p53 sequence analysis.1352 T Brodowicz et al
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atmosphere without CO2). Medium containing retinoids and/or
IFN-a-2b was replaced every 24 h. (3H)Thymidine (Amersham
International Life Science, plc, Buckinghamshire, UK), at a
concentration of 0.5 mCi per well, was included for the final 16 h.
The incorporation of (3H)Thymidine into DNA was measured
by a Direct Beta Counter-Matrix 96 (Packard, Groningen, The
Netherlands) after the cells were harvested with the Harvester
Micromate 196 (Packard, Groningen, The Netherlands) onto Glass
Fiber Filters (Packard, Groningen, the Netherlands). Experiments
were always done in triplicate. Data are presented as a percentage
of proliferation of untreated cells for each respective time point.
DNA fragmentation assay analysed by flow cytometry
The 3´OH termini in DNA breaks were measured by attaching
fluorescent tagged deoxyuridine triphosphate nucleotides FITC-
dUTP, in a reaction catalysed by terminal deoxynucleotidyl trans-
ferase (TdT) using the Apo-DirectTM Kit (Phoenix Flow Systems,
San Diego, CA, USA) purchased from Pharmingen (San Diego,
CA, USA). The amount of incorporated fluorescein was detected
by flow cytometry.
HTB-82, HTB-91, HTB-92, HTB-93 and HTB-94 soft tissue
sarcoma cell lines (1 ´106in T-25 flasks) were incubated with 9cRA,
13cRA or tRA (final concentrations: 10–7 M, 10–6 M, 10–5 M) for 48,
72, 96 and 120 h respectively. In addition, the same experiments were
performed with IFN-a-2b (final concentration: 1000 U ml–1) ±9cRA,
13cRA or tRA (final concentrations: 10–7 M, 10–6 M, 10–5 M).
Untreated and treated cells were harvested, washed twice in
phosphate-buffered saline (PBS), fixed in 1% (w/v) paraformalde-
hyde in PBS (pH 7.2), for 15 min on ice. After sedimentation and
two more washing steps, cells were resuspended in ice-cold 70%
(v/v) ethanol and stored at –20°C until further use (maximum: 3
weeks). According to the manufacturer’s instructions, cells were
washed twice in wash buffer, resuspended in 50 ml staining solu-
tion (10 ml reaction buffer, 0.75 ml TdT, 8 ml FITC-dUTP and
32 ml distilled water) and incubated for 1 h at 37°C. Afterwards,
1 ml rinsing buffer was added. Cells were centrifuged (1000 g) and
rinsed again. Subsequently, cells were resuspended in 1 ml
propidium iodine (PI)/RNAase solution and incubated in the dark
for 30 min at room temperature. Subsequently, cell samples were
analysed by flow cytometry on a FACScan (Becton Dickinson,
CA, USA).
Morphological evaluation of apoptosis
Cell morphology was performed by staining with May–
Gruenwald–Giemsa. For this reason, cells were cultured in
chamber slides (‘Lab-Tek Chamber Slide w/cover Glass Slide 2
Well’) (Nalge Nunc International, Naperville, USA). Treated and
untreated cells were stained with May–Gruenwald (Merck,
Darmstadt, Germany) for 5 min. Subsequently, cells were washed
with aqua dest (Leopold Pharma, Graz, Austria) for 5 min and
stained with Giemsa (Merck, Darmstadt, Germany) (diluted 1:10)
for 20 min. After a final wash with aqua dest, samples were viewed
under light microscopy. Cells were considered to be apoptotic
according to the criteria introduced by Kerr et al (1972) which
included: compaction of the nuclear chromatin, fragmentation of
nuclei, condensation of the cytoplasm and separation of the cell
into apoptotic bodies.
p53 immunohistochemistry
Immunohistochemical staining for the p53 protein was carried out
using a mouse monoclonal IgG2a antibody (Clone: DO-1;
Immunotech, Marseille, France; diluted 1:20) directed against
wild-type and mutant p53 protein. For p53 staining, cytocentri-
fugates were fixed with Merckofix fixation spray (Merck,
Darmstadt, Germany). After blocking with horse serum, samples
were incubated with the primary antibody for 1 h. Further
immunohistochemical staining was performed according to the
ABC-method, using products from Vector Laboratories
(Burlingame, CA, USA). Briefly, after incubation with the primary
antibody and incubation with a biotinylated antimouse antibody,
incubation with the ABC complex for 45 min followed. The
reaction product was developed with diaminobenzidine tetra-
hydrochloride. Finally, slides were counterstained with Gill’s
haematoxylin. All steps of incubation were performed at room
temperature.
p53 sequence analysis
Total genomic tumour DNA was extracted from 2 ´ 107 cells using
AB
Figure 1 Immunohistochemistry of soft tissue sarcoma cell lines for p53 protein. No overexpression of p53 was found in cell line HTB-91 (fibrosarcoma: A);
whereas cell line HTB-92 (liposarcoma) showed intense nuclear staining (B)Induction of proliferation inhibition and apoptosis induced by interferon-a and retinoids 1353
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standard phenol–chloroform extraction methods. Exons 2–11 of
the p53 gene were amplified separately using oligonucleotide
primers placed in the adjacent intron regions as described
previously (Lehman et al, 1991). Polymerase chain reaction (PCR)
products were controlled for purity, quantity and quality by
subjecting 5 m1 of PCR products to pre-cast 6% acrylamide/bis-
acrylamide gels (Novex, San Diego, CA, USA) using the pBR322
DNA-MspI digest as reference standard (Clontech Labs Inc., Palo
Alto, CA, USA). To remove residual single-stranded primers, 5 ml
of PCR products were enzymatically treated with combination of
exonuclease I and shrimp alkaline phosphatase (United States
Biochemical, Cleveland, OH, USA). Pretreated PCR products
were then directly sequenced using the Cycle Sequencing Kit
(Roche Molecular Systems, Inc. Branchburg, NJ, USA), utilizing
Ampli TaqR DNA Polymerase and a35S labelled dATP (DuPont
NEN, Brussel, Belgium). For each reaction (for the four
nucleotides), 0.5 ml of the thermostable DNA polymerase provided
in the kit were added at last to the reaction mix containing 2 ml
reaction buffer, 2–4 ml of enzymatically pretreated PCR product,
0.5 pmol unique primer (separate reaction for each exon) and
water to adjust total volume to 20 ml. After running, the 8%
acrylamide/bis-acrylamide gels are dried for 90 min at 70°C and
directly subjected to autoradiography against the Bio Max-MR
film (Kodak, New Haven, CT, USA). Mutations found were
confirmed by at least one complete reanalysis.
Detection of bcl-2 by immunofluorescence
Cells (1 ´ 106 in T-25 flasks) were incubated with 9cRA, 13cRA or
tRA (final concentrations: 10–7 M, 10–6 M, 10–5 M) for 48, 72, 96 and
120 h respectively. In addition, the same experiments were
performed with IFN-a-2b (final concentration: 1000 U ml–1) ±9cRA,
13cRA or tRA (final concentrations: 10–7 M, 10–6 M, 10–5 M). After
harvesting and three washes with PBS cells were fixed and permeabi-
lized with the fix and perm cell permeabilization kit (An der Grub,
Bio Research Gmbh, Kaumberg, Austria). According to the manu-
facturer’s instructions, 106 cells per sample were resuspended in 100
ml fixation medium and incubated for 15 min at room temperature.
Afterwards, 5 ml PBS were added. Cells were centrifuged
(5 min at 300 g) and subsequently resuspended in 100 ml permeabi-
lization medium and 10 ml FITC-conjugated monoclonal mouse IgG1
anti-human bcl-2 antibody (clone 124; DAKO, Glostrup, Denmark),
vortexed at low speed for 2 s and incubated for 15 min at room
temperature. After one more washing step, cells were analysed by
flow cytometry on a FACScan (Becton Dickinson, CA, USA).
Northern blotting for RAR mRNA expression
STS cells were plated in T-75 tissue culture flask (Costar) and
were grown to sub-confluence (see above). The total RNA was
extracted by a one-step acid guanidinium isothiocyanate–phenol
procedure using RNAzol (Biotecx, Houston, TX, USA) and 20 mg
of the RNA were loaded into each lane and were electrophoresed
for 4 h at 50 V in a 1% formaldehyde-containing agarose gel. The
separated RNA was then diffusion-blotted overnight onto nylon
membranes (Schleicher & Schuell, Dassel, Germany) and immobi-
lized by UV-cross-linking. RAR- and GAPDH-specific cDNA
probes were labelled with 32P-dCTP (New England Nuclear,
Vienna, Austria) using the random oligonucleotide primer exten-
sion kit (Stratagene, La Jolla, CA, USA). The membranes were
hybridized overnight at 65°C, washed twice with 2 ´ saline-
sodium citrate (SSC) and 0.1% sodium dodecyl sulphate (SDS) at
37°C and twice with 0.1 ´ SSC and 0.1% SDS at 65°C and were
exposed at –80°C to Kodak X-OMAT AR film (Eastman Kodak,
Rochester, NY, USA) between two intensifying screens. The blots
were then stripped and reprobed (overnight, 65°C) with the
GAPDH cDNA as an internal control to monitor the quantity and
integrity of the loaded RNA samples.
RESULTS
p53 genotype and protein expression
Native cell lines HTB-82, HTB-91, HTB-92, HTB-93 and HTB-94
were screened for their p53 genotype as well as their p53 protein
expression. p53 gene mutations are characterized in Table 1: HTB-
91, HTB-92 and HTB-94 cell lines had mutations in the p53 gene,
whereas wild-type p53 was found in HTB-82 and HTB-93 cell
lines. Immunohistochemistry for p53 revealed intense nuclear
staining in HTB-92 (Figure 1B) and HTB-94 cells, whereas HTB-
82, HTB-91 (Figure 1A) and HTB-93 cells showed no nuclear
staining. The p53 mutation of HTB-91 cells was probably associ-
ated with loss of protein staining.
Proliferation inhibition
To test the influence of retinoids and IFN-a on proliferation, STS
cell lines were incubated with IFN-a and/or retinoids for 48, 72,
96 and 120 h respectively. Figure 2 shows that IFN-a dose- and
time-dependently inhibited the proliferation of all five STS cell
lines at concentrations ranging from 25 U ml–1 to 1000 U ml–1 and
incubation periods from 48 to 120 h. It has to be noted, however,
that the inhibitory potential of IFN-a exerted upon various tested
cell lines varied with ranges between 49 and 77% (Figure 2).
Similarly, 9cRA, 13cRA or tRA showed a dose- (10–7 M, 10–6 M
and 10–5 M) and time-dependent proliferation inhibitory effect on
cell lines HTB-82 and HTB-93 (Figure 2). In contrast, HTB-91,
HTB-92 and HTB-94 could not be inhibited in their proliferation
by either 9cRA or 13cRA or tRA (Figure 2). Coincubation of
HTB-82, HTB-91, HTB-92, HTB-93 and HTB-94 STS cells with
retinoids and IFN-a did not further increase the antiproliferative
effect of IFN-a (data not shown). In control experiments, DMSO
only had no inhibitory influence upon either of the five cell lines
after any duration of incubation.
Induction of apoptosis: DNA fragmentation, analysis of
cell cycle position and DNA content
Induction of apoptosis by retinoids or IFN-a in STS cell lines was
investigated by DNA strand-break analysis. In order to analyse cell
cycle position of STS cells, global DNA content was measured with
PI counterstaining. HTB-82, HTB-91, HTB-92, HTB-93 or HTB-94
STS cells were incubated with 9cRA, 13cRA or tRA (final concen-
trations: 10–7 M, 10–6 M and 10–5 M) and/or IFN-a (1000 U ml–1) for
48, 72, 96 or 120 h respectively. DNA histograms obtained from
STS cell lines and the respective percentages of apoptotic and non-
apoptotic cells after 96 h incubation with 10–5 M of the appropriate
retinoid are shown in Figure 3. In summary, apoptosis could be
induced by retinoids 9cRA or tRA in cell lines HTB-82 and HTB-93
dose-dependently with an optimal duration of incubation with 10–5 M
of the appropriate retinoid for 96 h (Figure 3), whereas no apoptosis
was found in cell lines HTB-91, HTB-92 and HTB-94 during anInduction of proliferation inhibition and apoptosis induced by interferon-a and retinoids 1355
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incubation period of up to 120 h. In addition, treatment of HTB-82
and HTB-93 cells with 9cRA or tRA was associated with some
G1–S arrest. Finally, neither 13cRA nor IFN-a induced apoptosis in
either cell line. In detail, the results of induction of apoptosis in
correlation with cell cycle positions were as follows.
HTB-93 (synovial sarcoma)
After 96 h of incubation with 9cRA (10–5 M), the percentage of
apoptotic cells was 41% (G1: 35%; G2 and S: 6%) versus 59% non-
apoptotic cells (G1: 43%; G2 and S: 16%). At lower doses of 9cRA
(10–6 M and 10–7 M) we observed 29 and 20% apoptotic cells
respectively. After incubation with tRA (10–5 M) 50% of the cells
(G1: 45%; G2 and S: 5%) underwent apoptosis versus 50%
non-apoptotic cells (G1: 38%; G2 and S: 12%). At a concentration
of 10–6 M of tRA, 36% of cells showed apoptosis and 25% at 10–7 M.
No apoptosis was induced by either retinoid by incubation for 48 h.
HTB-82 (rhabdomyosarcoma)
Only tRA was capable of inducing apoptosis. After 96 h of incuba-
tion 89% (G1: 67%; G2 and S: 22%) of the cells were apoptotic.
Control 9cRA tRA
97% non-apopt.
3% apopt.
59% non-apopt.
41% apopt.
50% non-apopt.
50% apopt.
98% non-apopt.
2% apopt.
99% non-apopt.
1% apopt.
98% non-apopt.
2% apopt.
97% non-apopt.
3% apopt.
99% non-apopt.
1% apopt.
98% non-apopt.
2% apopt.
11% non-apopt.
89% apopt.
100%
non-apopt.
99% non-apopt.
1% apopt.
94% non-apopt.
6% apopt.
97% non-apopt.
3% apopt.
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Figure 3 FACS histograms of specifically for apoptosis stained soft tissue sarcoma cell lines after incubation without (control) or with 10–5 M 9-cis-retinoic acid
(9cRA) or all-trans-retinoic acid (tRA) for 96 h. FACS histograms show on the x-axis the log fluorescence intensity of non-apoptotic and  apoptotic cells within
the tested cell population. The y-axis represents the relative number of cells1356 T Brodowicz et al
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Eleven per cent of the cells did not undergo apoptosis (G1: 9%; G2
and S: 2%). At lower concentrations of tRA (10–6 M and 10–7 M) we
observed 50 and 41% apoptotic cells respectively.
HTB-91 (fibrosarcoma), HTB-92 (liposarcoma) and HTB-94
(chondrosarcoma)
No apoptosis was measured after treatment with 9cRA, 13cRA,
tRA and/or IFN-a. Neither 13cRA nor IFN-a in any concentration
(10–7–10–5 M; 25–1000 U ml–1) and after any length of incubation
(48–120 h) were capable of inducing apoptosis in either cell line.
Moreover, the addition of IFN-a to retinoids which were able to
induce apoptosis did not increase their apoptotic potency (data not
shown). Finally, incubation of all five cell lines with DMSO only
did not induce apoptosis after any time interval (data not shown).
Morphologic evaluation of apoptosis
Morphology of cells shown to undergo apoptosis by flow cytom-
etry exhibited typical apoptotic features such as nuclear-chromatin
compaction, cytoplasma condensation around the nucleus, cell
shrinkage and apoptotic ‘bodies’ (Figure 4).
bcl-2 protein expression
The effects of 9cRA, 13cRA and tRA on bcl-2 protein expression
were also studied. All five native cell lines (HTB-82, HTB-91,
HTB-92, HTB-93 and HTB-94) weakly expressed bcl-2 protein
(10–20%). Treatment of these cell lines with 9cRA, 13cRA and
tRA (final concentrations: 10–7 M, 10–6 M, 10–5 M) for 48, 72, 96 and
120 h respectively, did not modify the expression of bcl-2 protein.
Expression of RAR isoforms
None of the five STS cell lines expressed RAR-a and RAR-b
mRNA at levels detectable by Northern blot analysis. However,
RAR-g-specific transcripts with molecular sizes of approximately
3.3 kb were found in variable amounts in all cell lines (Figure 5).
Thus, the differential response of STS cell lines to retinoids was
not associated with a lack of RARs in general, or with a defect in
the expression of the universal retinoid receptor RAR-g in partic-
ular, or with a specific pattern of RAR isoform expression.
Correlation of p53 status with proliferation inhibition
and apoptosis
Normal p53 was found in cell lines in which retinoids 9cRA or
tRA were capable of inducing apoptosis and in which retinoids
9cRA, 13cRA and tRA led to proliferation inhibition. In contrast,
mutant p53 was present in cell lines in which retinoids were not
able to induce either apoptosis or proliferation inhibition (Table 2).
However, proliferation inhibition induced by IFN-a occurred in all
cell lines irrespective of their p53 status (Table 2). In control
experiments, p53 genotype as well as p53 protein expression did
not change after incubation of STS cell lines HTB-82,-91, -92, -93
and -94 with 9cRA, 13cRA or tRA (final concentrations:
10–7 M, 10–6 M and 10–5 M) and/or IFN-a (final concentrations: 25,
50, 100 and 1000 U ml–1) for 48, 72, 96 or 120 h (data not shown).
DISCUSSION
In response to DNA damage, wild-type p53 has been shown to
induce either cell cycle arrest in the G1 phase (Kastan et al, 1991;
Di Leonardo et al, 1994), allowing for DNA repair, or apoptosis
(Yonish-Rouach et al, 1991). In addition, wild-type p53 is also
responsible for the regulation of the cell cycle (Harvey et al, 1993)
during which p53-mediated arrests have been reported to occur not
only in the G1, but also in the G2 phases (Ryan et al, 1993;
Agarwal et al, 1995; Stewart et al, 1995). The final decision
whether induction of p53 triggers G1 arrest or apoptosis
Figure 4 May–Gruenwald–Giemsa staining of HTB-82 cells
(rhabdomyosarcoma) after incubation with all-trans-retinoic acid (10–5 M) for
72 h. Cells show typical apoptotic features such as nuclear-chromatin
compaction, cytoplasma condensation around the nucleus, cell shrinkage
and apoptotic ‘bodies’
12345
RAR-g
GAPDH
Figure 5 RAR-g mRNA expression in five different human soft tissue
sarcoma cell lines. Northern blot analysis was performed on 20 mg RNA
using a 32P-labelled RAR-g cDNA probe (upper panel). After autoradiography,
the membranes were stripped and reprobed with a 32P-labelled GAPDH
cDNA as an internal loading control (lower panel). Lane 1: HTB-92; lane 2:
HTB-93; lane 3: HTB-91; lane 4: HTB-94; lane 5: HTB-82Induction of proliferation inhibition and apoptosis induced by interferon-a and retinoids 1357
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(Slichenmyer et al, 1993) is thought to be dependent on the pres-
ence of a growth factor which provides a survival signal (Canman
et al, 1995). However, additional p53-independent apoptotic path-
ways exist in normal as well as malignant cells which differ in
their sensitivity towards apoptosis-inducing agents (Delia et al,
1993; Bracey et al, 1995; Shao et al, 1995; Thompson, 1995).
Retinoids exert a broad spectrum of biologic effects, including
inhibition of cell growth and induction of apoptosis in a variety
of cancer cell lines (Lotan, 1995). These biological effects are
thought to result from modulation of gene expression mediated by
nuclear receptors, including RARs which are expressed in three
different isoforms (RAR-a, RAR-b and RAR-g; Mangelsdorf et al,
1995). Although it has been generally accepted that retinoid-
triggered apoptosis mainly involves p53-dependent pathways
(Lovat et al, 1997; Toma et al, 1997), recent reports have provided
evidence about the possibility of retinoid-induced apoptosis inde-
pendent of p53 (Dmitrovsky, 1997; Giandomenico et al, 1997;
Oridate et al, 1997).
In the present investigation, we have shown that the mechanisms
of proliferation inhibition and induction of apoptosis in cells
derived from STS lines varying in p53 mutations can act indepen-
dently from the used agents. Thus, IFN-a was found to induce
inhibition of proliferation independently from the cells’ p53 status,
whereas the inhibition of proliferation achieved by retinoids was
associated with intact p53 and was not found in cells with p53
mutations. Considering its important regulatory potential upon
blocking apoptosis (Hockenbery et al, 1990), no influence of bcl-2
within the context of the reported findings was detectable in the
present model. Nevertheless, the degree of inhibition of prolifera-
tion varied between cell lines depending upon the chosen retinoid,
its concentration and time. In order to illustrate the actual inhibi-
tion of cellular proliferation rather than the induction of apoptosis,
a thymidine incorporation assay was used which proved DNA
synthesis occurred thus providing a direct parameter for cellular
proliferation and its actual inhibition. These findings suggest that
p53 status and its influence upon proliferation inhibition in STS
cell lines acted independently from and changed with the used
preparation. It is conceivable, therefore, that proliferation inhibi-
tion induced by IFN-a used a different pathway independent from
p53 (Dmitrovsky, 1997; Giandomenico et al, 1997; Oridate et al,
1997) the functionality of which is important, however, for the
activity exerted by retinoids in the same context.
In contrast to its antiproliferative effect, IFN-a did not have the
ability to induce apoptosis in the tested STS cell lines. In contrast,
tRA was capable of inducing apoptosis in cell lines HTB-82 and
HTB-93, and 9cRA in cell line HTB-93, whereas 13cRA did not
induce apoptosis, at all. However, no induction of apoptosis by
otherwise effective retinoids 9cRA or tRA occurred in cell lines
HTB-91, HTB-92 and HTB-94 in which mutations of p53 were
found. Data obtained from Northern blot analysis demonstrated
that resistance to induction of apoptosis induced by retinoids in the
three STS cell lines harbouring mutations of the p53 gene did not
result from a defect in the expression of RARs indicating that p53
did not regulate RAR-a, -b or -g expression in these instances. As
RAR-g constitutes a universal receptor for the used retinoids (Repa
et al, 1997; Fisher et al, 1998), a defect in the presence of a relevant
receptor can be excluded as an explanation for our findings. Thus,
no simple correlation of retinoid sensitivity with the expression
pattern of RARs could be established for STS cell lines which is in
accordance with previous reports (Van der Leede et al, 1993;
Engers et al, 1996). Although p53-mutated HTB-92 and HTB-94
cell lines showed intensive nuclear staining by immunohistochem-
istry, the p53 mutated HTB-91 cell line showed no nuclear staining.
The p53 mutation in HTB-91 is probably related to a loss of protein
staining (Aas et al, 1996). It is, therefore, interesting to note that the
inhibition of proliferation by retinoids was closely linked to their
ability to induce apoptosis, suggesting the importance of p53 in
both contexts. It is noteworthy, however, that 13cRA – while being
able to inhibit cellular proliferation – did not induce apoptosis, thus
further suggesting a possible divergence of mechanisms regulating
the two phenomena. This assumption is supported by recent reports
that have demonstrated that 13cRA did not bind to RARs on its
own (Wu et al, 1994; Berggren et al, 1995). In summary, an
overview of our data suggests that only mutations of p53 correlated
with an abrogation of proliferation inhibition and of induction of
apoptosis by retinoids 9cRA and tRA.
Regarding the possible clinical impact of our data, we report an
antiproliferative influence of IFN-a and certain retinoids as well as
the induction of apoptosis by the latter group of drugs, which could
constitute the basis for clinical studies in patients with STS, espe-
cially when cytotoxic chemotherapy has failed. In similarity to this
assumption, recent reports have already reported about the successful
inclusion of retinoids in the treatment of certain malignancies
(Tallman et al, 1997). Concerning STS, however, our results have
shown that the histological subtype and p53 status might predict the
efficacy of this therapy. The latter aspect could also be valid for
the use of cytotoxic therapy which often has failed to produce
convincing results in STS in the adjuvant or palliative setting.
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